JPH06503311A - 薬理学的に活性なイオン化可能物質を含有する新規な医薬製剤およびその製造法 - Google Patents
薬理学的に活性なイオン化可能物質を含有する新規な医薬製剤およびその製造法Info
- Publication number
- JPH06503311A JPH06503311A JP4500116A JP50011692A JPH06503311A JP H06503311 A JPH06503311 A JP H06503311A JP 4500116 A JP4500116 A JP 4500116A JP 50011692 A JP50011692 A JP 50011692A JP H06503311 A JPH06503311 A JP H06503311A
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- resin
- formulation
- hydrophilic
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 13
- 239000000126 substance Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 30
- 239000011347 resin Substances 0.000 claims description 23
- 229920005989 resin Polymers 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 239000003456 ion exchange resin Substances 0.000 claims description 8
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 6
- 229960002237 metoprolol Drugs 0.000 claims description 6
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical group COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 230000000536 complexating effect Effects 0.000 claims 2
- 229960002796 polystyrene sulfonate Drugs 0.000 claims 2
- 239000011970 polystyrene sulfonate Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 7
- 229960000939 metoprolol succinate Drugs 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- -1 poly(acrylic acid) Polymers 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- GQWWGRUJOCIUKI-UHFFFAOYSA-N 2-[3-(2-methyl-1-oxopyrrolo[1,2-a]pyrazin-3-yl)propyl]guanidine Chemical compound O=C1N(C)C(CCCN=C(N)N)=CN2C=CC=C21 GQWWGRUJOCIUKI-UHFFFAOYSA-N 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 2
- 229960002213 alprenolol Drugs 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 2
- 229960005105 terbutaline sulfate Drugs 0.000 description 2
- IPYJWACEFWLBMV-UHFFFAOYSA-N 2-(1h-indol-3-ylmethyl)-1,3-thiazolidine-4-carboxylic acid Chemical compound N1C(C(=O)O)CSC1CC1=CNC2=CC=CC=C12 IPYJWACEFWLBMV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- DOKHEARVIDLSFF-UHFFFAOYSA-N prop-1-en-1-ol Chemical group CC=CO DOKHEARVIDLSFF-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (12)
- 1.活性物質の長期間放出のための薬理学的に活性なイオン化可能物質の製剤で あって、活性物質がイオン交換樹脂とイオン的に錯体化され、そして生成した錯 体が親水性で崩壊性のマトリックス中に埋込まれる該製剤。
- 2.経口的用途のための請求項1記載の製剤。
- 3.イオン交換樹脂が活性物質と反対に帯電した架橋ポリマーである請求項2記 載の製剤。
- 4.10%以上の親水性マトリックスがポリサッカリドまたはその誘導体で構成 される請求項2記載の製剤。
- 5.親水性マトリックスがヒドロキシプロピルメチルセルロースである請求項4 記載の製剤。
- 6.ヒドロキシプロピルメチルセルロースが低いおよび高い分子量のヒドロキシ プロピルメチルセルロースを共に含有する請求項5記載の製剤。
- 7.活性物質が塩基であり、そして樹脂がカチオン交換体である請求項3記載の 製剤。
- 8.活性物質が酸であり、そして樹脂がアニオン交換体である請求項3記載の製 剤。
- 9.活性物質がメトプロロールであり、そして樹脂がポリスチレンスルホネート である請求項7記載の製剤。
- 10.活性物質がテルブタリンであり、そして樹脂がポリスチレンスルホネート である請求項7記載の製剤。
- 11.イオン化可能な活性物質が10mg/ml以上の溶解度を有する請求項2 記載の製剤。
- 12.a)活性物質を反対に帯電したイオン交換体にイオン的に錯体化して錯体 を生成し、 b)該錯体を親水性で崩壊性のマトリックス中に埋込み、そして c)得られる混合物を適当な公知の方法により錠剤化することを特徴とする請求 項1記載の製剤の製造法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9003903A SE9003903D0 (sv) | 1990-12-07 | 1990-12-07 | New pharmaceutical formulations |
PCT/SE1991/000814 WO1992010171A1 (en) | 1990-12-07 | 1991-12-03 | New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof |
SE9003903-3 | 1991-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06503311A true JPH06503311A (ja) | 1994-04-14 |
JP3276956B2 JP3276956B2 (ja) | 2002-04-22 |
Family
ID=20381122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50011692A Expired - Fee Related JP3276956B2 (ja) | 1990-12-07 | 1991-12-03 | 薬理学的に活性なイオン化可能物質を含有する新規な医薬製剤およびその製造法 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5707656A (ja) |
EP (1) | EP0560816B1 (ja) |
JP (1) | JP3276956B2 (ja) |
AT (1) | ATE444737T1 (ja) |
AU (1) | AU656346B2 (ja) |
CA (1) | CA2097176C (ja) |
DE (1) | DE69133623D1 (ja) |
EE (1) | EE03105B1 (ja) |
FI (1) | FI932553A0 (ja) |
HU (1) | HU218661B (ja) |
IE (1) | IE914136A1 (ja) |
IS (1) | IS1749B (ja) |
NO (1) | NO305536B1 (ja) |
PT (1) | PT99720B (ja) |
SE (1) | SE9003903D0 (ja) |
WO (1) | WO1992010171A1 (ja) |
YU (1) | YU186791A (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU736308B2 (en) * | 1996-12-20 | 2001-07-26 | Warner-Lambert Company Llc | Antitussive drugs delivered by ion exchange resins |
WO2001008661A2 (en) * | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
KR20030034171A (ko) * | 2001-07-06 | 2003-05-01 | 엔도 파마슈티걸즈, 인크. | 옥시모르폰 제어 방출 제형 |
US20030099711A1 (en) * | 2001-08-29 | 2003-05-29 | David Meadows | Sustained release preparations |
EP1499295A4 (en) * | 2002-04-05 | 2006-04-05 | Penwest Pharmaceuticals Co | EXTENDED RELEASE METOPROLOL FORMULATIONS |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
JP2006296511A (ja) * | 2005-04-15 | 2006-11-02 | Transcutaneous Technologies Inc | 外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ |
JP2006346368A (ja) * | 2005-06-20 | 2006-12-28 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びその製造方法 |
US20090214625A1 (en) * | 2005-07-15 | 2009-08-27 | Mizuo Nakayama | Drug delivery patch |
JP2007037868A (ja) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | 経皮投与装置及びその制御方法 |
US8386030B2 (en) * | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
WO2007026671A1 (ja) * | 2005-08-29 | 2007-03-08 | Transcu Ltd. | センサからの情報により投与すべき薬剤の選定を行うイオントフォレーシス装置 |
AU2006289888B2 (en) * | 2005-09-16 | 2010-12-02 | Tti Ellebeau, Inc. | Catheter type iontophoresis apparatus |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
WO2007038028A1 (en) * | 2005-09-28 | 2007-04-05 | Tti Ellebeau, Inc. | Iontophoresis apparatus and method to deliver active agents to biological interfaces |
EP1941929A1 (en) * | 2005-09-30 | 2008-07-09 | Tti Ellebeau, Inc. | Electrode structure for iontophoresis comprising shape memory separator, and iontophoresis apparatus comprising the same |
CN101277737A (zh) * | 2005-09-30 | 2008-10-01 | Tti优而美株式会社 | 将多种活性剂输送至生物界面的离子电渗装置 |
US20090187134A1 (en) * | 2005-09-30 | 2009-07-23 | Hidero Akiyama | Iontophoresis Device Controlling Amounts of a Sleep-Inducing Agent and a Stimulant to be Administered and Time at Which the Drugs are Administered |
US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
EP2123259A1 (en) * | 2007-01-16 | 2009-11-25 | Hokkaido University | Liposome preparation for iontophoresis having antioxidant component encapsulated therein |
JP2010187707A (ja) * | 2007-06-12 | 2010-09-02 | Hokkaido Univ | インスリンを封入したイオントフォレーシス用リポソーム製剤 |
MX2011002529A (es) * | 2008-09-10 | 2011-07-29 | Transcu Ltd | Aparato y metodo para suministrar liquidos viscosos basados en hpc dentro de substratos porosos, por ejemplo un proceso basado en una banda continua. |
WO2010115015A1 (en) * | 2009-04-03 | 2010-10-07 | Coating Place, Inc. | Modified-release pharmaceutical drug composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983392A (en) * | 1983-11-14 | 1991-01-08 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
EP0199855A1 (en) * | 1985-05-02 | 1986-11-05 | Gist-Brocades N.V. | Tablets comprising tromethoprim and a sulfonamide |
JPS62223112A (ja) * | 1986-03-25 | 1987-10-01 | Rooto Seiyaku Kk | 歯周病治療剤 |
IE62100B1 (en) * | 1986-07-30 | 1994-12-14 | Fisons Corp | Coated ion exchange resins |
DE3740684A1 (de) * | 1987-12-01 | 1989-06-15 | Woehr Otto Gmbh | Parksystem |
MC2025A1 (fr) * | 1988-04-20 | 1990-04-25 | Asta Pharma Ag | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee |
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5149523A (en) * | 1989-06-20 | 1992-09-22 | Aktiebolaget Hassle | Polystyrenesulfonate-drug complex and solid dosage forms thereof |
-
1990
- 1990-12-07 SE SE9003903A patent/SE9003903D0/xx unknown
-
1991
- 1991-11-27 YU YU186791A patent/YU186791A/sh unknown
- 1991-11-28 IE IE413691A patent/IE914136A1/en not_active Application Discontinuation
- 1991-12-03 WO PCT/SE1991/000814 patent/WO1992010171A1/en active Application Filing
- 1991-12-03 AT AT91920634T patent/ATE444737T1/de not_active IP Right Cessation
- 1991-12-03 EP EP91920634A patent/EP0560816B1/en not_active Expired - Lifetime
- 1991-12-03 JP JP50011692A patent/JP3276956B2/ja not_active Expired - Fee Related
- 1991-12-03 HU HU9301671A patent/HU218661B/hu not_active IP Right Cessation
- 1991-12-03 CA CA002097176A patent/CA2097176C/en not_active Expired - Fee Related
- 1991-12-03 DE DE69133623T patent/DE69133623D1/de not_active Expired - Fee Related
- 1991-12-03 AU AU89305/91A patent/AU656346B2/en not_active Ceased
- 1991-12-04 US US07/802,325 patent/US5707656A/en not_active Expired - Lifetime
- 1991-12-06 IS IS3787A patent/IS1749B/is unknown
- 1991-12-06 PT PT99720A patent/PT99720B/pt active IP Right Grant
-
1993
- 1993-06-04 NO NO932053A patent/NO305536B1/no not_active IP Right Cessation
- 1993-06-04 FI FI932553A patent/FI932553A0/fi unknown
-
1994
- 1994-03-22 US US08/216,028 patent/US5709882A/en not_active Expired - Lifetime
- 1994-11-17 EE EE9400416A patent/EE03105B1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE444737T1 (de) | 2009-10-15 |
HUT64213A (en) | 1993-12-28 |
CA2097176C (en) | 2002-03-26 |
YU186791A (sh) | 1994-04-05 |
HU218661B (hu) | 2000-10-28 |
PT99720A (pt) | 1992-10-30 |
US5707656A (en) | 1998-01-13 |
PT99720B (pt) | 2002-04-29 |
EP0560816A1 (en) | 1993-09-22 |
NO305536B1 (no) | 1999-06-21 |
IS3787A7 (is) | 1992-06-08 |
FI932553A (fi) | 1993-06-04 |
FI932553A0 (fi) | 1993-06-04 |
JP3276956B2 (ja) | 2002-04-22 |
WO1992010171A1 (en) | 1992-06-25 |
AU656346B2 (en) | 1995-02-02 |
CA2097176A1 (en) | 1992-06-08 |
NO932053D0 (no) | 1993-06-04 |
HU9301671D0 (en) | 1993-09-28 |
EP0560816B1 (en) | 2009-10-07 |
AU8930591A (en) | 1992-07-08 |
US5709882A (en) | 1998-01-20 |
IE914136A1 (en) | 1992-06-17 |
DE69133623D1 (de) | 2009-11-19 |
IS1749B (is) | 2000-07-11 |
NO932053L (no) | 1993-07-20 |
EE03105B1 (et) | 1998-08-17 |
SE9003903D0 (sv) | 1990-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06503311A (ja) | 薬理学的に活性なイオン化可能物質を含有する新規な医薬製剤およびその製造法 | |
DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
JP2825202B2 (ja) | 調剤用イオン交換樹脂組成物の製法 | |
US3074852A (en) | Pharmaceuticals with delayed release | |
US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
JP2916152B2 (ja) | 薬物放出速度調節型製剤 | |
US6531153B2 (en) | Composition with sustained release of levodopa and carbidopa | |
JPH0751516B2 (ja) | 固体医薬製剤 | |
JPS62195322A (ja) | 持効性ドラッグデリバリーマトリックスシステム | |
JPH02172912A (ja) | 徐放性薬物‐樹脂複合体 | |
JPS58403B2 (ja) | L− アスコルビンサンセイザイノ セイゾウホウ | |
Motycka et al. | Influence of wax coatings on release rate of anions from ion‐exchange resin beads | |
DE69712033T2 (de) | Anionenaustauscherharze enthaltende tabletten | |
JPS6335526A (ja) | ポリマ−処理イオン交換樹脂 | |
JPH09202732A (ja) | 陰イオン交換樹脂を含有する錠剤 | |
JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
JPH02218621A (ja) | 徐放性製剤 | |
JPS62132830A (ja) | 徐放性医薬品組成物 | |
EP1020184A1 (en) | Sustained release tablets containing bupropion hydrochloride | |
HRP921038A2 (en) | New pharmaceutical formulations containing a macologically active ionizable substance as well as ess for the preparation thereof | |
JP4696210B2 (ja) | イソソルビド‐5‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 | |
JPH10182448A (ja) | 圧縮製剤用組成物の製造方法 | |
TWI284043B (en) | Ion-strength independent sustained release pharmaceutical formulation | |
SI9111867A (sl) | Nove farmacevtske formulacije, ki vsebujejo aktivno ionizirajočo snov, kot tudi postopek za njihovo pripravo | |
JPH0624964A (ja) | ヒドロモルホンスフェロイド調整放出製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080208 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090208 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090208 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100208 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |